[go: up one dir, main page]

NI202100080A - 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión - Google Patents

5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión

Info

Publication number
NI202100080A
NI202100080A NI202100080A NI202100080A NI202100080A NI 202100080 A NI202100080 A NI 202100080A NI 202100080 A NI202100080 A NI 202100080A NI 202100080 A NI202100080 A NI 202100080A NI 202100080 A NI202100080 A NI 202100080A
Authority
NI
Nicaragua
Prior art keywords
disorder
dimethyltryptamine
dmt
meo
depression
Prior art date
Application number
NI202100080A
Other languages
English (en)
Inventor
Terwey Theis
Original Assignee
Gh Res Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65529503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI202100080(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gh Res Ireland Limited filed Critical Gh Res Ireland Limited
Publication of NI202100080A publication Critical patent/NI202100080A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan composiciones para su uso en el tratamiento de un paciente que padece un trastorno mental en particular trastorno depresivo mayor, trastorno depresivo persistente, trastorno de ansiedad, trastornos de estrés postraumático, trastorno dismórfico corporal, trastornos obsesivo compulsivo, trastorno alimentario y abuso de sustancias psicoactivas. Se proporcionan además regímenes de dosificación para tratar estos trastornos.
NI202100080A 2019-02-22 2021-08-20 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión NI202100080A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19158774 2019-02-22

Publications (1)

Publication Number Publication Date
NI202100080A true NI202100080A (es) 2021-12-06

Family

ID=65529503

Family Applications (1)

Application Number Title Priority Date Filing Date
NI202100080A NI202100080A (es) 2019-02-22 2021-08-20 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión

Country Status (32)

Country Link
US (2) US20220071958A1 (es)
EP (3) EP4349407B1 (es)
JP (2) JP7598326B2 (es)
KR (1) KR20210154966A (es)
CN (1) CN114555078A (es)
AU (1) AU2020225410B2 (es)
BR (1) BR112021016153A2 (es)
CA (1) CA3130406A1 (es)
CL (1) CL2021002174A1 (es)
CO (1) CO2021010882A2 (es)
CR (1) CR20210437A (es)
DK (2) DK3927337T3 (es)
DO (1) DOP2021000176A (es)
EA (1) EA202192318A1 (es)
EC (1) ECSP21060868A (es)
ES (2) ES3031965T3 (es)
FI (2) FI4349407T3 (es)
HR (2) HRP20250590T1 (es)
HU (2) HUE071841T2 (es)
IL (1) IL285537A (es)
LT (2) LT4349407T (es)
MA (1) MA55021B1 (es)
MD (1) MD3927337T2 (es)
MX (2) MX2021009941A (es)
NI (1) NI202100080A (es)
PE (1) PE20220015A1 (es)
PL (2) PL4349407T3 (es)
PT (2) PT4349407T (es)
RS (2) RS65706B1 (es)
SI (2) SI4349407T1 (es)
SM (1) SMT202400154T1 (es)
WO (1) WO2020169850A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220071958A1 (en) 2019-02-22 2022-03-10 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3753923A1 (en) * 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
PT3873883T (pt) 2019-11-07 2023-03-24 Small Pharma Ltd Método de síntese
EP3868364A1 (en) * 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
PH12022553135A1 (en) 2020-05-19 2024-03-04 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
EP4595962A3 (en) 2020-06-12 2025-10-22 Beckley Psytech Limited Pharmaceutical composition
JP7567024B2 (ja) * 2020-08-05 2024-10-15 ユニヴェルシテートスピタル バーゼル Ｄｍｔ補助心理療法のための静脈内ｄｍｔ投与方法
EP4200021A1 (en) 2020-08-18 2023-06-28 Cybin IRL Limited Therapeutic phenethylamine compositions and methods of use
AU2021334933B2 (en) * 2020-08-28 2023-01-19 Cybin Uk Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
CA3194558A1 (en) * 2020-10-02 2022-04-07 Brett J. GREENE Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
CN112138028A (zh) * 2020-10-10 2020-12-29 南京中医药大学 蟾蜍色胺类物质在制备抗抑郁药物中的应用
WO2022082058A1 (en) * 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Method of treatment by tryptamine alkaloids
WO2022117640A1 (en) * 2020-12-01 2022-06-09 Small Pharma Ltd Inhalable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US20220265582A1 (en) * 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
CA3113414A1 (en) * 2021-03-29 2022-09-29 Mind Cure Health Inc. Psychedelics protocol computer systems and methods
BR112023022195A2 (pt) 2021-04-26 2024-01-16 Atai Therapeutics Inc Novas composições e métodos de n,n-dimetiltriptamina
US20230136824A1 (en) 2021-04-26 2023-05-04 ATAI Life Sciences AG N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
JP2024517194A (ja) * 2021-05-03 2024-04-19 マインド メディシン， インコーポレイテッド サイケデリック薬の用量を漸増する方法
WO2022235927A1 (en) * 2021-05-05 2022-11-10 Gilgamesh Pharmaceuticals, Inc. Novel tryptamines and methods of treating mood disorders
MX2023013928A (es) 2021-05-25 2023-12-08 Atai Therapeutics Inc Nuevas sales y formas cristalinas de sales de n,n-dimetiltriptamina.
JP2024522174A (ja) 2021-06-09 2024-06-11 アタイ セラピューティクス， インコーポレイテッド ジメチルトリプタミンの新規プロドラッグおよびコンジュゲート
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (en) * 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
JP2024540527A (ja) * 2021-11-18 2024-10-31 サイビン ユーケー リミテッド 注射製剤及び吸入製剤
US12012381B2 (en) 2021-12-30 2024-06-18 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
EP4499074A1 (en) 2022-03-27 2025-02-05 GH Research Ireland Limited 5-meo-dtm for the treatment of bipolar disorder
AU2023244452A1 (en) 2022-03-27 2024-11-07 GH Research Ireland Limited Treatment of cognitive dysfunction
RS65585B1 (sr) 2022-03-27 2024-06-28 Gh Res Ireland Limited Kristalna so 5-meo-dmt hidrobromid
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
WO2024160391A1 (en) 2023-01-30 2024-08-08 GH Research Ireland Limited Treatment of mental disorders
IL322428A (en) 2023-01-30 2025-09-01 Gh Res Ireland Limited 5-Methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in nursing mothers
GB202306256D0 (en) * 2023-04-27 2023-06-14 Beckley Psytech Ltd 5-Methoxy-N,N-Dimethyltryptamine Formulations
WO2024251807A1 (en) * 2023-06-08 2024-12-12 Cybin Irl Limited Companion animal treatments
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025068714A1 (en) * 2023-09-28 2025-04-03 Beckley Psytech Limited Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
WO2025087962A1 (en) 2023-10-23 2025-05-01 Reconnect Labs Ag Pharmaceutical formulations comprising 5-meo-dmt and their therapeutic uses
WO2025111597A1 (en) * 2023-11-22 2025-05-30 Gilgamesh Pharmaceuticals, Inc. A treatment for patients with mood disorders using n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine or a pharmaceutically acceptable salt thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
JP2007516404A (ja) 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ， インコーポレイテッド 光学点火されたかまたは電気点火された内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット
ES2355983T3 (es) 2006-08-01 2011-04-01 STOBI GMBH & CO. KG Balón de válvula para inhaladores .
CN103816150A (zh) * 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
EP3713568A1 (en) * 2017-10-26 2020-09-30 Consejo Superior de Investigaciones Cientificas (CSIC) Combination product for the treatment of neurological and/or psychiatric disorders
US20220071958A1 (en) 2019-02-22 2022-03-10 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression

Also Published As

Publication number Publication date
JP7598326B2 (ja) 2024-12-11
KR20210154966A (ko) 2021-12-21
US20220071958A1 (en) 2022-03-10
EP4353314A2 (en) 2024-04-17
SI3927337T1 (sl) 2024-07-31
RS66912B1 (sr) 2025-07-31
US20240307350A1 (en) 2024-09-19
CO2021010882A2 (es) 2022-01-17
PT4349407T (pt) 2025-06-04
DK3927337T3 (da) 2024-04-22
IL285537A (en) 2021-09-30
AU2020225410A1 (en) 2021-08-19
CA3130406A1 (en) 2020-08-27
EP4353314A3 (en) 2024-07-03
JP2022521337A (ja) 2022-04-06
BR112021016153A2 (pt) 2021-10-05
MX2025002567A (es) 2025-04-02
ECSP21060868A (es) 2021-11-30
EP4349407B1 (en) 2025-04-09
PT3927337T (pt) 2024-05-17
EA202192318A1 (ru) 2021-12-21
LT4349407T (lt) 2025-07-10
HRP20250590T1 (hr) 2025-07-04
SI4349407T1 (sl) 2025-06-30
HUE071841T2 (hu) 2025-09-28
EP3927337B8 (en) 2024-03-20
PL3927337T3 (pl) 2024-07-29
JP2025029035A (ja) 2025-03-05
CN114555078A (zh) 2022-05-27
FI3927337T3 (fi) 2024-05-08
EP3927337B1 (en) 2024-02-14
SMT202400154T1 (it) 2024-07-09
DK4349407T3 (da) 2025-05-26
RS65706B1 (sr) 2024-08-30
MA55021A (fr) 2021-12-29
MX2021009941A (es) 2021-12-10
DOP2021000176A (es) 2021-11-21
PL4349407T3 (pl) 2025-07-21
AU2020225410B2 (en) 2025-10-30
MD3927337T2 (ro) 2024-08-31
CR20210437A (es) 2021-11-02
EP3927337A1 (en) 2021-12-29
HUE066828T2 (hu) 2024-09-28
HRP20240532T1 (hr) 2024-07-19
ES2984438T3 (es) 2024-10-29
MA55021B1 (fr) 2024-05-31
ES3031965T3 (en) 2025-07-14
LT3927337T (lt) 2024-07-10
EP4349407A2 (en) 2024-04-10
CL2021002174A1 (es) 2022-01-28
EP4349407A3 (en) 2024-07-03
FI4349407T3 (fi) 2025-06-02
WO2020169850A1 (en) 2020-08-27
PE20220015A1 (es) 2022-01-11

Similar Documents

Publication Publication Date Title
NI202100080A (es) 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión
MX2025000197A (es) Composiciones que comprenden 5-metoxi-n, n-dimetiltriptamina (5-meo- dmt) para su uso en el tratamiento de trastornos mentales
MX2025007468A (es) Composiciones y metodos para el manejo de trastornos
CO2018013654A2 (es) Composiciones nasales de cannabidiol
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
NI201700137A (es) Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue
MX2019002265A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2021005797A2 (es) Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia
Kassan et al. Chronic escitalopram treatment induces erectile dysfunction by decreasing nitric oxide bioavailability mediated by increased nicotinamide adenine dinucleotide phosphate oxidase activity and reactive oxygen species production
BR112017023425A2 (pt) combinações terapêuticas de terapias antivirais e anti-inflamatórias
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
CL2022001079A1 (es) Métodos y composiciones para el tratamiento del síndrome de rett
Fusco et al. The impact of non-urologic drugs on sexual function in men
CL2019003172A1 (es) Brimonidina destinada al uso y diseño de ensayos clínicos para la atrofia geográfica debido a una degeneración macular asociada a la edad.
BR112018009476A2 (pt) regime de dosagem de plasminogênio para cicatrização de ferimentos
AR116592A1 (es) Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
BR112018015483A2 (pt) formulações farmacêuticas sólidas estáveis que contêm 2-(2-nitro-4-trifluorometil-benzoil)-1,3 -ciclo-hexanodiona
MX2022014198A (es) Usos y formulaciones de los cannabinoides.
MX2022005375A (es) Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con neoplasias mieloproliferativas (nmp) con navitoclax.
MX2023006855A (es) Formas de dosificacion y usos terapeuticos de l-4-cloro quinurenina
BR112019000711A2 (pt) xibornol como um agente virucida para uso no tratamento profilático ou terapêutico de uma infecção causada por um ou mais vírus e composto farmacêutico virucida
AR102494A1 (es) Métodos para tratar enfermedades oculares